Research ArticleArticle

Survival and Causes of Death in an Unselected and Complete Cohort of Norwegian Patients with Systemic Sclerosis

Anna-Maria Hoffmann-Vold, Øyvind Molberg, Øyvind Midtvedt, Torhild Garen and Jan Tore Gran
The Journal of Rheumatology July 2013, 40 (7) 1127-1133; DOI: https://doi.org/10.3899/jrheum.121390

REFERENCES

  1. 1.↵
    1. Giordano M,
    2. Valentini G,
    3. Migliaresi S,
    4. Picillo U,
    5. Vatti M
    . Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 1986;13:911–6.
    OpenUrlPubMed
  2. 2.↵
    1. Steen VD,
    2. Powell DL,
    3. Medsger TA Jr.
    . Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988;31:196–203.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Radstake TR,
    2. Gorlova O,
    3. Rueda B,
    4. Martin JE,
    5. Alizadeh BZ,
    6. Palomino-Morales R,
    7. et al.
    Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 2010;42:426–9.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Masi AT,
    2. Rodnan GP,
    3. Medsger TA Jr.,
    4. Altman RD,
    5. D’Angelo WA,
    6. Fries JF
    . Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581–90.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. LeRoy EC,
    2. Medsger TA Jr.
    . Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573–6.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Chifflot H,
    2. Fautrel B,
    3. Sordet C,
    4. Chatelus E,
    5. Sibilia J
    . Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008;37:223–35.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Hoffmann-Vold AM,
    2. Midtvedt O,
    3. Molberg O,
    4. Garen T,
    5. Gran JT
    . Prevalence of systemic sclerosis in south-east Norway. Rheumatology 2012;51:1600–5.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Simeon CP,
    2. Armadans L,
    3. Fonollosa V,
    4. Solans R,
    5. Selva A,
    6. Villar M,
    7. et al.
    Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology 2003;42:71–5.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Ioannidis JP,
    2. Vlachoyiannopoulos PG,
    3. Haidich AB,
    4. Medsger TA Jr.,
    5. Lucas M,
    6. Michet CJ,
    7. et al.
    Mortality in systemic sclerosis: An international meta-analysis of individual patient data. Am J Med 2005;118:2–10.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Jacobsen S,
    2. Halberg P,
    3. Ullman S
    . Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 1998;37:750–5.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Geirsson AJ,
    2. Wollheim FA,
    3. Akesson A
    . Disease severity of 100 patients with systemic sclerosis over a period of 14 years: Using a modified Medsger scale. Ann Rheum Dis 2001;60:1117–22.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Hachulla E,
    2. Carpentier P,
    3. Gressin V,
    4. Diot E,
    5. Allanore Y,
    6. Sibilia J,
    7. et al.
    Risk factors for death and the 3-year survival of patients with systemic sclerosis: The French ItinerAIR-Sclerodermie study. Rheumatology 2009;48:304–8.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Ferri C,
    2. Valentini G,
    3. Cozzi F,
    4. Sebastiani M,
    5. Michelassi C,
    6. La Montagna G,
    7. et al.
    Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 2002;81:139–53.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Hesselstrand R,
    2. Scheja A,
    3. Akesson A
    . Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998;57:682–6.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Lee P,
    2. Langevitz P,
    3. Alderdice CA,
    4. Aubrey M,
    5. Baer PA,
    6. Baron M,
    7. et al.
    Mortality in systemic sclerosis (scleroderma). Q J Med 1992;82:139–48.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Steen VD,
    2. Medsger TA Jr.
    . Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437–44.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Czirjak L,
    2. Kumanovics G,
    3. Varju C,
    4. Nagy Z,
    5. Pakozdi A,
    6. Szekanecz Z,
    7. et al.
    Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 2008;67:59–63.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Arias-Nunez MC,
    2. Llorca J,
    3. Vazquez-Rodriguez TR,
    4. Gomez-Acebo I,
    5. Miranda-Filloy JA,
    6. Martin J,
    7. et al.
    Systemic sclerosis in northwestern Spain: A 19-year epidemiologic study. Medicine 2008;87:272–80.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Steen VD,
    2. Medsger TA
    . Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 2007;66:940–4.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Kuo CF,
    2. See LC,
    3. Yu KH,
    4. Chou IJ,
    5. Tseng WY,
    6. Chang HC,
    7. et al.
    Epidemiology and mortality of systemic sclerosis: a nationwide population study in Taiwan. Scand J Rheumatol 2011;40:373–8.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Simeon CP,
    2. Armadans L,
    3. Fonollosa V,
    4. Vilardell M,
    5. Candell J,
    6. Tolosa C,
    7. et al.
    Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis. Ann Rheum Dis 1997;56:723–8.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Scussel-Lonzetti L,
    2. Joyal F,
    3. Raynauld JP,
    4. Roussin A,
    5. Rich E,
    6. Goulet JR,
    7. et al.
    Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine 2002;81:154–67.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Mayes MD,
    2. Lacey JV Jr.,
    3. Beebe-Dimmer J,
    4. Gillespie BW,
    5. Cooper B,
    6. Laing TJ,
    7. et al.
    Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246–55.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Vanthuyne M,
    2. Smith V,
    3. De Langhe E,
    4. Van Praet J,
    5. Arat S,
    6. Depresseux G,
    7. et al.
    The Belgian Systemic Sclerosis Cohort: correlations between disease severity scores, cutaneous subsets, and autoantibody profile. J Rheumatol 2012;39:2127–33.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Karassa FB,
    2. Ioannidis JP
    . Mortality in systemic sclerosis. Clin Exp Rheumatol 2008;26 Suppl 51:S85–93.
    OpenUrlPubMed
  26. 26.↵
    1. Moore OA,
    2. Goh N,
    3. Corte T,
    4. Rouse H,
    5. Hennessy O,
    6. Thakkar V,
    7. et al.
    Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology 2013;52:155–60.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Sampaio-Barros PD,
    2. Bortoluzzo AB,
    3. Marangoni RG,
    4. Rocha LF,
    5. Del Rio AP,
    6. Samara AM,
    7. et al.
    Survival, causes of death, and prognostic factors in systemic sclerosis: analysis of 947 Brazilian patients. J Rheumatol 2012;39:1971–8.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Derk CT,
    2. Huaman G,
    3. Littlejohn J,
    4. Otieno F,
    5. Jimenez S
    . Predictors of early mortality in systemic sclerosis: A case-control study comparing early versus late mortality in systemic sclerosis. Rheumatol Int 2012;32:3841–4.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Hesselstrand R,
    2. Scheja A,
    3. Wuttge DM
    . Scleroderma renal crisis in a Swedish systemic sclerosis cohort: survival, renal outcome, and RNA polymerase III antibodies as a risk factor. Scand J Rheumatol 2012;41:39–43.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Komocsi A,
    2. Vorobcsuk A,
    3. Faludi R,
    4. Pinter T,
    5. Lenkey Z,
    6. Kolto G,
    7. et al.
    The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies. Rheumatology 2012;51:1027–36.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Elhai M,
    2. Meune C,
    3. Avouac J,
    4. Kahan A,
    5. Allanore Y
    . Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology 2012;51:1017–26.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Silman AJ
    . Scleroderma and survival. Ann Rheum Dis 1991;50:267–9.
    OpenUrlFREE Full Text
  33. 33.↵
    1. Altman RD,
    2. Medsger TA Jr.,
    3. Bloch DA,
    4. Michel BA
    . Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991;34:403–13.
    OpenUrlPubMed
  34. 34.↵
    1. Jacobsen S,
    2. Ullman S,
    3. Shen GQ,
    4. Wiik A,
    5. Halberg P
    . Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 2001;28:2454–9.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Tyndall AJ,
    2. Bannert B,
    3. Vonk M,
    4. Airo P,
    5. Cozzi F,
    6. Carreira PE,
    7. et al.
    Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809–15.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Galie N,
    2. Hoeper MM,
    3. Humbert M,
    4. Torbicki A,
    5. Vachiery JL,
    6. Barbera JA,
    7. et al.
    Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493–537.
    OpenUrlFREE Full Text
  37. 37.↵
    1. Launay D,
    2. Humbert M,
    3. Berezne A,
    4. Cottin V,
    5. Allanore Y,
    6. Couderc LJ,
    7. et al.
    Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. Chest 2011;140:1016–24.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Goh NS,
    2. Desai SR,
    3. Veeraraghavan S,
    4. Hansell DM,
    5. Copley SJ,
    6. Maher TM,
    7. et al.
    Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008;177:1248–54.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Bryan C,
    2. Howard Y,
    3. Brennan P,
    4. Black C,
    5. Silman A
    . Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 1996;35:1122–6.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    1. Wigley FM,
    2. Denton C
    . Scleroderma: from pathogenesis to comprehensive management. New York, Dordrecht, Heidelberg, London: Springer; 2012.
  41. 41.↵
    1. Masi AT
    . Classification of systemic sclerosis (scleroderma): relationship of cutaneous subgroups in early disease to outcome and serologic reactivity. J Rheumatol 1988;15:894–8.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Save to my folders

Jump to section

Keywords

SYSTEMIC SCLEROSIS
EPIDEMIOLOGY
MORTALITY
SURVIVAL
CONNECTIVE TISSUE DISEASES

Keywords